首頁 > 市場調查報告書 > 製藥

骨疾病

骨質疏鬆症治療市場規模、佔有率和成長分析：按藥物類別、性別、給藥途徑、通路和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2091749

骨質疏鬆症治療市場規模、佔有率和成長分析：按藥物類別、性別、給藥途徑、通路和地區分類－2026-2033年產業預測

Osteoporosis Treatment Market Size, Share, and Growth Analysis, By Drug Class (Bisphosphonates, Denosumab), By Gender (Female, Male), By Route, By Distribution, By Region - Industry Forecast 2026-2033

出版日期: 2026年07月14日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球骨質疏鬆症治療市場價值為 145.2 億美元，預計到 2025 年將成長至 154.1 億美元，到 2033 年將成長至 248.5 億美元，在預測期（2026-2033 年）內複合年成長率為 6.12%。

全球骨質疏鬆症治療市場涵蓋多種藥物、生物製藥和醫療設備，旨在預防骨質流失和降低骨折風險。全球數百萬人口老化加劇，推動了對有效治療方法的需求。伴隨預期壽命延長而來的人口結構變化，尤其對骨骼密度下降的女性和老年男性造成影響，促使保險公司和醫療機構採取預防措施。在市場發展歷程中，治療手段已從簡單的補充劑轉向更先進的療法，包括雙磷酸鹽和單株抗體。此外，保險報銷模式越來越與降低骨折風險的療效掛鉤，迫使製造商投資於能夠證明成本效益的研究。對於那些能夠整合診斷和治療、推廣個人化方案、控制長期成本並提高患者用藥依從性的公司而言，存在著巨大的商機。

全球骨質疏鬆症治療市場的成長要素

骨質疏鬆症盛行率的上升主要受人口老化影響，導致骨折高風險族群數量增加。隨著骨骼密度下降，患者和醫療保健提供者都在積極尋求預防和治療方案，從而增加了對已通過核准療法的需求。人們對該疾病對生活品質的負面影響的認知不斷提高，促使早期診斷和持續用藥，進而刺激了學名藥和創新藥的市場活動。此外，隨著社會老化和醫療保健系統面臨的財政壓力不斷增加，人們越來越需要政策措施來加強骨骼健康管理和改善治療可近性，這將進一步推動市場擴張。

全球骨質疏鬆症治療市場的阻礙因素

創新骨質疏鬆症療法的高昂費用對患者和醫療保健系統都構成了重大障礙，尤其是在保險覆蓋不足的地區。當治療費用超出「可承受範圍」時，醫療專業人員可能會猶豫是否開立這些先進療法，轉而選擇療效可能較差的舊療法，從而阻礙了新療法的廣泛應用。此外，保險報銷的複雜性，例如漫長的核准週期和不一致的承保政策，也增加了尋求治療的患者的不確定性。因此，支付方和患者雙方對費用的敏感度抑制了需求，儘管這些新療法具有臨床益處，但市場成長卻受到阻礙。

全球骨質疏鬆症治療市場趨勢

全球骨質疏鬆症治療市場正經歷著向個人化醫療的顯著轉變。醫療專業人員擴大採用基於基因型的治療方案，以根據個別骨骼代謝特徵最佳化藥物選擇和劑量。這種方法不僅提高了治療效果，還最大限度地減少了不利事件，符合不斷發展的以患者為中心的醫療模式。製藥創新者正積極將生物標記納入臨床試驗設計，加速開發新世代針對特定風險表現型的藥物。因此，保險公司越來越重視基於精準醫療的以結果為導向的療法，市場也正轉向能夠更好地滿足不同患者群體需求並改善長期健康結果的個人化骨質疏鬆症治療方案。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Amgen Inc.（Prolia）
UCB SA（Evenity）
Eli Lilly（Forteo）
Pfizer Inc.
Merck & Co.
Novartis AG
Roche
AstraZeneca
Radius Health（Abaloparatide）
Servier Laboratories
Warner Chilcott
Shire（Takeda）
Chugai Pharmaceutical
Kyowa Kirin
Gedeon Richter
Sun Pharmaceutical
Teva Pharmaceutical
Mylan（Viatris）
Dr. Reddy's Laboratories
Cipla Ltd.

結論與建議

簡介目錄

Product Code: SQMIG35I3211

Global Osteoporosis Treatment Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 15.41 Billion in 2025 to USD 24.85 Billion by 2033, growing at a CAGR of 6.12% during the forecast period (2026-2033).

The Global Osteoporosis Treatment Market encompasses a range of pharmaceuticals, biologics, and medical devices focused on preventing bone loss and reducing fracture risks. Driven by a growing aging population, with millions affected globally, there is an increasing demand for effective treatment options. The demographic shift towards higher life expectancy particularly affects women and older men with declining bone density, encouraging insurers and healthcare providers to implement preventive measures. Market evolution showcases a historical progression from simple supplements to sophisticated therapies, including bisphosphonates and monoclonal antibodies. Additionally, reimbursement models are increasingly tied to demonstrated effectiveness in reducing fractures, prompting manufacturers to invest in research showcasing cost savings. Opportunities arise for companies integrating diagnostics with treatment, facilitating personalized approaches and enhancing adherence while managing long-term costs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Osteoporosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Osteoporosis Treatment Market Segments Analysis

Global osteoporosis treatment market is segmented by drug class, gender, route, distribution and region. Based on drug class, the market is segmented into Bisphosphonates, Denosumab, Teriparatide, SERMs and Romosozumab. Based on gender, the market is segmented into Female and Male. Based on route, the market is segmented into Oral, Injectable and Intravenous. Based on distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Osteoporosis Treatment Market

The rising prevalence of osteoporosis is significantly influenced by an aging population, which results in a higher number of individuals susceptible to fractures. As bone density diminishes, both patients and healthcare providers actively pursue preventive and therapeutic solutions, thereby increasing the demand for approved treatment options. Heightened awareness about the disease's detrimental effects on quality of life encourages early diagnosis and consistent medication adherence, subsequently stimulating activity within the market for both generic and innovative products. Furthermore, as societies age and financial pressures on healthcare systems grow, there is a corresponding push for policy measures that enhance bone health management and improve treatment accessibility, further bolstering market expansion.

Restraints in the Global Osteoporosis Treatment Market

The substantial expense associated with innovative osteoporosis therapies represents a considerable obstacle for both patients and healthcare systems, especially in regions where insurance coverage is inadequate. When the costs of treatment surpass what is deemed affordable, healthcare providers may hesitate to prescribe these advanced options, opting instead for older and potentially less effective alternatives, which hinders the acceptance of new therapies. Additionally, the intricacies of reimbursement, including prolonged approval times and inconsistent coverage policies, add to the uncertainty for patients seeking treatment. As a result, the sensitivity to costs among both payers and patients restricts demand, impeding market growth despite the clinical advantages provided by these novel treatments.

Market Trends of the Global Osteoporosis Treatment Market

The Global Osteoporosis Treatment market is witnessing a significant trend towards personalized therapeutics, where healthcare providers are increasingly adopting genotype-guided treatment pathways to customize drug choices and dosing based on individual bone metabolism profiles. This approach not only enhances therapeutic effectiveness but also minimizes adverse events, aligning with evolving patient-centric care models. Pharmaceutical innovators are actively integrating biomarkers into clinical trial designs, speeding up the development of next-generation agents that address specific risk phenotypes. As a result, payers are increasingly favoring therapies that showcase precision-driven outcomes, leading to a market shift toward tailored osteoporosis solutions that better serve diverse patient segments and improve long-term health outcomes.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Osteoporosis Treatment Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Bisphosphonates
Denosumab
Teriparatide
SERMs
Romosozumab

Global Osteoporosis Treatment Market Size by Gender & CAGR (2026-2033)

Market Overview
Female
Male

Global Osteoporosis Treatment Market Size by Route & CAGR (2026-2033)

Market Overview
Oral
Injectable
Intravenous

Global Osteoporosis Treatment Market Size by Distribution & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online

Global Osteoporosis Treatment Market Size & CAGR (2026-2033)

North America (Drug Class, Gender, Route, Distribution)
- US
- Canada
Europe (Drug Class, Gender, Route, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Gender, Route, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Gender, Route, Distribution)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Gender, Route, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Amgen Inc. (Prolia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB SA (Evenity)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly (Forteo)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radius Health (Abaloparatide)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Servier Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Warner Chilcott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire (Takeda)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gedeon Richter
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments